Hong Kong based OrbusNeich has announced the European launch of their Genous Bio-engineered Cobalt Chromium Stent, which supposedly accelerates the endovascular healing process and reduces the risk of restenosis compared to current bare-metal and drug-eluting stents. The stent’s patented design provides high radial strength, which allows the stent to be thinner, and the incorporation of Genous technology is touted by the company to result in faster healing by trapping endothelial progenitor cells at the implantation site.
From the press release:
The thin cobalt chromium stent struts exhibit a low profile and great flexibility for ideal deliverability, while the dual helix stent design provides superior radial strength and excellent sidebranchability for effective bifurcation stenting. The combination of the Genous technology with the new platform provides physicians with a stent designed to modulate restenosis and protect against thrombosis.
Press release: OrbusNeich Announces Full Availability of Genous(TM) Bio-engineered Cobalt Chromium Stent Following CE Mark Approval
Product page: Genous CoCr